Results 1 to 10 of about 24,808 (160)

Over-the-counter access to combined oral contraceptives for individuals with hypertension: an expert review [PDF]

American Journal of Preventive Cardiology
Efforts are underway to move a combined oral contraceptive over the counter in the United States. However, hypertension is an important contraindication and questions exist regarding how users should screen for it in an over-the-counter setting.
Kate Grindlay, Katherine Key, Raegan McDonald-Mosley, Melissa Kottke, Dázon Dixon Diallo, Martha Gulati, Daniel Grossman   +6 more
doaj   +2 more sources

Combined Oral Contraceptives and the Risk of Thrombosis. [PDF]

Int J Mol Sci
Combined oral contraceptives (COCs) remain one of the most popular reversible contraceptive methods worldwide. Still, regardless of the drug composition and duration of therapy, almost all COCs are associated with the risk of venous thrombosis. This review highlights the main pathogenetic mechanisms of thrombosis development during oral contraceptive ...
Khizroeva J, Bitsadze V, Sukhikh G, Tretyakova M, Gris JC, Elalamy I, Gerotziafas G, Kapanadze D, Kvaratskheliia M, Tatarintseva A, Khisamieva A, Hovancev I, Yakubova F, Makatsariya A.   +13 more
europepmc   +3 more sources

The effect of lavender on mood disorders associated with the use of combined oral contraceptives (COCs): a triple-blinded randomized controlled trial [PDF]

BMC Complementary Medicine and Therapies
Background The use of contraceptive methods is influenced by their effectiveness, availability, and minimal side effects. OCPs are one of the most effective and widely used methods of pregnancy prevention worldwide.
Mina Naghdi, Azizeh Farshbaf-Khalili, Jila Nahaee, Parvin Hakimi, Mahnaz Shahnazi   +4 more
doaj   +2 more sources

Oral contraceptives and tissue factor expression. Comments on “Do combined oral contraceptives induce formation of tissue factor?” [PDF]

Research and Practice in Thrombosis and Haemostasis
Bjarne Østerud
doaj   +2 more sources

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk [PDF]

Frontiers in Endocrinology, 2021
Laure Morimont, Hélène Haguet, Jonathan Douxfils   +2 more
exaly   +2 more sources

Investigating cardiovascular risk in premenopausal women on oral contraceptives: Systematic review with meta-analysis

Frontiers in Cardiovascular Medicine, 2023
BackgroundThe use of oral contraceptives (OCs) is associated with an increased risk of cardiovascular events such as arterial and venous thrombosis (VTE).
Oyesanmi A. Fabunmi, Oyesanmi A. Fabunmi, Phiwayinkosi V. Dludla, Bongani B. Nkambule   +3 more
doaj   +1 more source

Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. [PDF]

PLoS ONE, 2014
PURPOSE: To estimate the number of venous thromboembolic events and related-premature mortality (including immediate in-hospital lethality) attributable to the use of combined oral contraceptives in women aged 15 to 49 years-old between 2000 and 2011 in ...
Aurore Tricotel, Fanny Raguideau, Cédric Collin, Mahmoud Zureik   +3 more
doaj   +1 more source

Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report

Research and Practice in Thrombosis and Haemostasis, 2020
Combined oral contraceptives and factor V Leiden mutation are multiplicative risk factors for venous thromboembolism. However, it remains unknown whether this multiplicative effect is reflected in thrombin generation assays.
Maxime G. Zermatten, Debora Bertaggia Calderara, Alessandro Aliotta, Lorenzo Alberio   +3 more
doaj   +1 more source

Reproductive behavior of medical students: realities of contraceptive choice [PDF]

Гинекология, 2018
Representations of the society about the use of hormonal drugs for protection from unwanted pregnancy have the features of a deeply rooted behavioral and social stigmatization.
T A Oboskalova, O V Prohorova
doaj   +1 more source

Thromboembolic safety of norethisterone vs levonorgestrel in combined oral contraceptive users: a pooled analysis of 4 large prospective cohort studiesAJOG Global Reports at a Glance

AJOG Global Reports, 2022
BACKGROUND: Norethisterone (acetate) and levonorgestrel are marketed globally as components of combined oral contraceptives. Although guidelines recommend both as first-line combined oral contraceptives, no direct, comparative safety studies are ...
Clare Barnett, MBBS (Hons), MPH, Anja Bauerfeind, PhD, Sophia Von Stockum, PhD, Klaas Heinemann, MD, PhD, MSc, MBA   +3 more
doaj   +1 more source